Inverse benefit law

From WikiMD.org
Jump to navigation Jump to search

Inverse Benefit Law

The Inverse Benefit Law is a concept in pharmacology and healthcare policy that suggests the ratio of benefits to harm among patients taking new drugs tends to vary inversely with how extensively a drug is marketed[1]. The term was coined by Donald Light and Joel Lexchin in 2012.

Pronunciation

  • Inverse: /ɪnˈvɜːrs/
  • Benefit: /ˈbɛnɪfɪt/
  • Law: /lɔː/

Etymology

The term "Inverse Benefit Law" is derived from the English words "inverse", "benefit", and "law". "Inverse" comes from the Latin inversus, the past participle of invertere, meaning 'turn upside down'. "Benefit" is from the Latin benefactum, from bene 'well' + factum, neuter past participle of facere 'do'. "Law" is from the Old English lagu, from the Old Norse lag, which means 'something laid down or fixed'.

Related Terms

See Also

References

  1. Light, Donald W.; Lexchin, Joel; Darrow, Jonathan J. (2013). "Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs". Journal of Law, Medicine & Ethics. 14 (3): 590–610.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski